相关实验视频

Updated: Jul 4, 2025

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

在扩展辅助疗法环境中,CTS5 是一个有用的决策工具吗?

Kerstin Wimmer^1,2, Dominik Hlauschek³, Marija Balic⁴

¹Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, Vienna, Austria. kerstin.wimmer@meduniwien.ac.at.

Breast cancer research and treatment

|January 25, 2024

概括

5年后的临床治疗评分 (CTS5) 可靠地预测激素受体阳性乳腺癌患者的晚期远程复发风险. 虽然它对低至中等风险进行了良好的校准,但在高风险组中显示出校准错误,并倾向于从延长的内分泌治疗中获益.

科学领域:

在瘤学瘤学.
临床医学临床医学
生物统计学生物统计学

背景情况:

5年后的临床治疗评分 (CTS5) 是激素受体阳性乳腺癌的预后工具.
内分泌疗法 (ET) 是标准的5年,但延长ET可能有利于选择患者.
ABCSG-06和-06a试验提供了评估CTS5实用性的数据.

研究的目的:

评估CTS5评分的预后值和校准准确性.
确定CTS5是否可以识别受益于延长内分泌治疗 (ET) 的患者.
为了评估晚期远程复发 (LDR) 的风险,超过5年的ET.

主要方法:

从ABCSG-06和-06a试验中对2114名患者进行前性分析.
考克斯回归模型被用来分析到LDR的时间.
评估CTS5的预测能力,校准和预测价值,以延长ET的好处.

主要成果:

在高风险和中等风险的CTS5组中观察到较高的LDR率 (HR分别为4.02和1.93).
增加的CTS5分数与增加的LDR风险相关 (HR 2.23).
在高风险患者中发现了CTS5的校准错误;一个趋势表明,延长ET (绝对LDR减少-6.1%) 有益.

结论:

CTS5是一种可靠的预后工具,适用于低风险和中等风险群体.
在高风险患者中,观察到的与预期的LDR率之间发现了实质性的差异.
该研究没有证实CTS5对延长ET益处的显著预测值,尽管有数值趋势.

关键词:

一个辅助的辅助.乳腺癌乳腺癌乳腺癌在CTS5中获得的分数.扩展内分泌疗法扩展内分泌疗法预测预测预测

更多相关视频

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.